


FIG. 1


SAHA Patient: IV vs ORAL (200 mg/dose)



Best Available Copy


FIG. 2

Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS Cohort I (200 mg/dose)



3/19

## FIG. 3




Best Available Copy

4/19

FIG. 4

Protocol 01-021 (ORAL SAHA)  
ARM A: SOLID TUMOR PATIENTS  
Cohort I (200 mg/dose)




Best Available Copy

5/19


FIG. 5

Protocol 01-021 (ORAL SAHA)  
ARM A: SOLID TUMOR PATIENTS  
Cohort IIa (400 mg/dose)



6/19

FIG. 6







FIG. 7

Protocol 01-021  
(ORAL SAHA)  
ARM A: SOLID  
TUMOR PATIENTS  
Cohort IIa (400 mg/dose)

8/19


FIG. 8





9/19


**FIG. 9A**  
Oral 200 mg vs. 400 mg (Fasting)  
Oral dose on Cycle 1 Day 8



10/19

**FIG. 9B**

Oral 200 mg vs. 400 mg (no-fasting)  
Oral Dose on Cycle 1 Day 9



11/19

**FIG. 9C**  
IV 200 mg vs. 400 mg  
IV Dose on Cycle 1 Day 1






FIG. 10

Apparent Half-life of the Oral Dose  
Half-life



13/19


**FIG. 11**  
AUC of the Oral  
Dose AUC<sub>last</sub>



14/19


**FIG. 12**

Bioavailability after 200 and 400 mg by Day



15/19

MESOTHELIOMA



PRE FIG. 13 POST

16/19





FIG. 14


A

B

Best Available Copy



17/19




B



A

FIG. 15

Best Available Copy



B


FIG. 16

A

Best Available Copy

**2 Months Post SAHA**

**Pre-Therapy**



**A**

**FIG. 17**

**B**

**Best Available Copy**